Press release

March 21, 2017

Prime Therapeutics Study Finds 97 Percent of Hepatitis C Patients Cured with Harvoni® Treatment

Real-world data show nearly all patients completing therapy were cured.

ST. PAUL, Minn. – Nearly all patients who completed at least eight weeks of hepatitis C treatment with Gilead’s Harvoni® (ledipasvir/sofosbuvir) were cured of the disease, according to Prime Therapeutics LLC (Prime). Prime, a pharmacy benefit manager (PBM) serving nearly 20 million members nationally will present the data next week at the Academy of Managed Care Pharmacy’s 2017 Annual Meeting. The results are similar to clinical trial data on the treatment, which found cure rates of 94 to 99 percent.

For the study, Prime researchers reviewed data from 311 individuals who received at least eight weeks of Harvoni therapy and had a sustained virologic response (SVR) test result provided to the pharmacy between 12 to 24 weeks following Harvoni use. The SVR is used determine treatment response. Researchers found 301 of 311 members (96.8 percent) had a SVR laboratory result indicating a cure.

“Prime’s real-world data reflect findings from clinical trials. Our members who received at least eight weeks of Harvoni through Prime Therapeutics Specialty PharmacyTM had a very high likelihood of being cured of this disease,” said Cathy Starner, PharmD, principal health outcomes researcher at Prime.

About Prime Therapeutics

Prime Therapeutics LLC (Prime) helps people get the medicine they need to feel better and live well. Prime manages pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid. The company processes claims and delivers medicine to members, offering clinical services for people with complex medical conditions. Prime serves nearly 20 million people. It is collectively owned by 14 Blue Cross and Blue Shield Plans, subsidiaries or affiliates of those plans.

Follow @Prime_PBM on Twitter.

Sign-up for regular news announcements from Prime Therapeutics.


Denise Lecher
Manager, Corporate Communications